These results indicate that SYTZD treatment led to a reduction in relative protein levels of mTOR, FASN, HIF-1α, and VEGFA and enhancement in relative protein levels of ESR1and p-GSK-3β in livers of NAFLD rats. This evidence concerns the gene VEGFA and metabolic dysfunction-associated steatotic liver disease.